Alliance for Pandemic Preparedness

May 28, 2020

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19



  • A randomized trial among hospitalized COVID-19 patients who did not require mechanical ventilation found no differences between a 5-day course and a 10-day course of remdesivir. By day 14, clinical improvement was observed in over half of patients in both treatment arms. However, this trial lacked a placebo control and could not determine if this improvement that was attributable to remdesivir. 

Goldman et al. (May 27, 2020). Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. The New England Journal of Medicine.